Skip to main content

Morning Overview

Thousands of bottles of a combination blood pressure pill are recalled nationwide

A pharmacy bottle of blood pressure pills is supposed to deliver the same dose from the first tablet to the last. For 3,744 bottles of one three-drug combination tablet shipped across the United States, the FDA record says the pills failed a test of how they dissolve, and the maker has been pulling them back since Oct. 7.

The product is olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets, distributed by Macleods Pharma USA of New Jersey. The FDA classified the recall on Oct. 26 as Class II, the middle tier, and patients are not being told to stop taking their medicine.

The two lots and what failed

According to FOX 9’s report on the FDA listing, two lots are involved. Lot 12251163A holds 3,528 bottles of 30 tablets (NDC 33342-246-07) and lot 12251163B holds 216 bottles of 90 tablets (NDC 33342-246-10). Both expire May 31, 2027. Together they make up the 3,744 bottles, and the recall covers nationwide distribution.

The reason on the FDA record is “failed dissolution specifications.” A tablet that dissolves too slowly or too little may not release its drug into the bloodstream at the intended rate, which could keep the medicine from lowering blood pressure as expected, as IBTimes reported citing USA Today. The same report says the affected product is the 40 mg olmesartan, 10 mg amlodipine and 12.5 mg hydrochlorothiazide strength, that brand-name Tribenzor is not part of the recall, and that Macleods notified recipients by letter; the outlet found no separate company press release. The FDA enforcement record, the outlet said, lists the recall as ongoing under recall number D-0077-2027.

Macleods could not be reached for comment, FOX 9 said. Cardiovascular Business describes the product as a generic version of Tribenzor, originally sold by Daiichi Sankyo, made by Macleods Pharmaceuticals in India and sold in the United States through the New Jersey subsidiary. IBTimes gives the manufacturing site as Daman, India.

What a dissolution test checks

Dissolution testing is a routine quality measure for tablets. The FDA’s dissolution methods database describes the procedure: samples are taken at set times to measure how much of the active drug has dissolved, normally at 37 degrees Celsius, and the agency generally recommends that at least 70 to 85 percent of the labeled drug dissolve by the last sampling time, depending on the product. A batch that falls short of its specification fails, even if every ingredient is present at the right strength.

That is why the FDA assigns this kind of failure a lower classification than contamination. In its enforcement report definitions, the agency says a Class II recall involves a product whose use may cause temporary or medically reversible health harm, or where the chance of serious harm is remote. The most serious tier covers a reasonable probability of serious adverse health consequences, and the lowest covers products unlikely to cause harm at all, so Class II sits between the two. FDA adds that classification of a recall “should not be seen as an expansion or change to a firm’s voluntary public warning,” and that firms often warn the public well before classification is finished.

What patients are told to do

The FDA’s recall guidance for consumers is specific. Patients should check the lot number on the bottle against the one in the recall notice. For Class II and III recalls, they can generally keep taking the medicine unless the company or the FDA says otherwise. The page warns that, in some instances, stopping a medicine may be more harmful to health than continuing to take the recalled one, so patients should not quit on their own.

The agency says to bring questions to a doctor or pharmacist and, if the company advises a return, to take the product back to where it was bought. The FDA’s consumer line is 1-888-463-6332. IBTimes notes that recalls at this level generally occur at the retail level, and that most retailers have return and refund policies for recalled products, though the lot and NDC match on the bottle is the first thing to check.

A year of dissolution failures

The Macleods recall is one of several this year for blood pressure drugs that missed quality specifications. the same Cardiovascular Business report listed 675 bottles of enalapril maleate tablets recalled in May for failing an organic impurities test, then more than 11,000 bottles of chlorthalidone tablets a month later for failed dissolution, a single lot of Novartis valsartan in August for failed dissolution, and more than 28,000 bottles of ramipril capsules in September for an out-of-specification result for dicyclohexylurea.

FOX 9 separately reported that Inventia Healthcare Ltd. of India recalled 13,567 bottles of 25 mg chlorthalidone tablets after a failed dissolution test. Neither report gives Inventia’s lot numbers or a statement from the company.

The unanswered detail is how far the Macleods failure extends. The two listed lots are the only batches named in the FDA record the reports cite, and the record does not say what the failing test results were.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.


More from Morning Overview


Morning Overview is reader-supported. Some links in our articles are affiliate links, and we may earn a commission at no extra cost to you. As an Amazon Associate I earn from qualifying purchases. Full disclosure.